Literature DB >> 21897272

Association of survivin gene polymorphism with endometrial cancer.

Parisa Zahedi1, Soheila Aminimoghaddam, Forough A Sayahpour, Vahid Haghpanah, Parvin Amiri, Forozandeh Fereidoni, Elnaz Mahrampour, Bagher Larijani, Javad Tavakkoly-Bazzaz, Mahsa M Amoli.   

Abstract

OBJECTIVE: Survivin is an inhibitor of apoptosis protein, which is up-regulated in endometrial cancer (EC). A promoter region polymorphism (-31G/C) in the survivin gene has been reported as a modulator of gene expression. The aim of this study was to explore the frequency of survivin -31G/C polymorphism in tumor tissues from patients with EC in an Iranian population compared to that of healthy controls.
MATERIALS AND METHODS: Paraffin-embedded tissue sections from patients diagnosed with EC (n = 31) and healthy controls (n = 30) were examined. Genotyping for survivin -31G/C polymorphism was performed using polymerase chain reaction (PCR) restriction fragment length polymorphism (RFLP).
RESULTS: The presence of allele C was found to be significantly increased in EC tissues compared to the healthy tissues (GG vs GC + CC, P = 0. 01; OR, 3.6; 95% CI, 1.1-11.9).
CONCLUSION: Our data are in keeping with a previous finding regarding the role of survivin gene polymorphism in malignancies. This finding highlights the role of survivin in pathogenesis of various carcinomas, which might have therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21897272     DOI: 10.1097/IGC.0b013e318229902c

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  10 in total

1.  Network analysis revealed aurora kinase dysregulation in five gynecological types of cancer.

Authors:  Shikha Suman; Ashutosh Mishra
Journal:  Oncol Lett       Date:  2017-11-08       Impact factor: 2.967

Review 2.  Association between survivin -31G>C polymorphism and cancer risk: meta-analysis of 29 studies.

Authors:  Qin Qin; Chi Zhang; Hongcheng Zhu; Xi Yang; Liping Xu; Jia Liu; Jing Lu; Liangliang Zhan; Hongyan Cheng; Xinchen Sun
Journal:  J Cancer Res Clin Oncol       Date:  2014-02       Impact factor: 4.553

3.  SURVIVIN POSITIVITY AND PROGNOSTIC FACTORS IN PAPILLARY THYROID CARCINOMAS.

Authors:  E Usturali Keskin; E Taştekin; N Can; A N Mut; M Celik; B Yilmaz Bulbul; F Oz Puyan; F Ozyilmaz; S Guldiken; S Ayturk; A Sezer; F Üstün
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Oct-Dec       Impact factor: 1.104

4.  Survivin rs9904341 (G>C) polymorphism contributes to cancer risk: an updated meta-analysis of 26 studies.

Authors:  Lei Xu; Xin Zhou; Lin Xu; Rong Yin
Journal:  Tumour Biol       Date:  2013-10-05

5.  Polymorphisms of BIRC5 Gene is Associated with Chronic HBV Infection in Iranian Population.

Authors:  Bita Moudi; Zahra Heidari; Hamidreza Mahmoudzadeh-Sagheb
Journal:  Indian J Clin Biochem       Date:  2019-01-02

6.  Prognostic Significance of Survivin Expression in Osteosarcoma Patients: A Meta-Analysis.

Authors:  Yugang Liu; Zhaowei Teng; Ying Wang; Pengfei Gao; Junli Chen
Journal:  Med Sci Monit       Date:  2015-09-25

Review 7.  Survivin: A molecular biomarker in cancer.

Authors:  Praveen Kumar Jaiswal; Apul Goel; R D Mittal
Journal:  Indian J Med Res       Date:  2015-04       Impact factor: 2.375

8.  Association of survivin polymorphisms with tumor susceptibility: a meta-analysis.

Authors:  Ying Zhu; Yongguo Li; Shisheng Zhu; Renkuan Tang; Yunzhi Liu; Jianbo Li
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

9.  Functional promoter -31G/C variant of Survivin gene predict prostate cancer susceptibility among Chinese: a case control study.

Authors:  Jiawei Chen; Xinhai Cui; Hai Zhou; Chao Qin; Qiang Cao; Xiaobing Ju; Pu Li; Hongzhou Cai; Jian Zhu; Xiaoxin Meng; Meilin Wang; Zhengdong Zhang; Pengfei Shao; Jie Li; Changjun Yin
Journal:  BMC Cancer       Date:  2013-07-24       Impact factor: 4.430

10.  Serum survivin increases in prolactinoma.

Authors:  Fatma Dilek Dellal; Mutlu Niyazoglu; Suheyla Gorar; Esranur Ademoglu; Zehra Candan; Handan Bekdemir; Yalcin Hacioglu; Fatih Oner Kaya
Journal:  J Clin Med Res       Date:  2015-02-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.